This is what analysts have to say about aTyr Pharma, Inc. (NASDAQ:LIFE) after last week.

November 10, 2018 - By olga

aTyr Pharma, Inc. (NASDAQ:LIFE) Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

Among 2 analysts covering aTyr Pharma (NASDAQ:LIFE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. aTyr Pharma had 3 analyst reports since May 15, 2018 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, August 15. The stock of aTyr Pharma, Inc. (NASDAQ:LIFE) earned “Sell” rating by Citigroup on Tuesday, May 15. As per Friday, August 17, the company rating was upgraded by Citigroup. Below is a list of aTyr Pharma, Inc. (NASDAQ:LIFE) latest ratings and price target changes.

17/08/2018 Broker: Citigroup Old Rating: Sell New Rating: Neutral Old Target: $1 New Target: $0.75 Upgrade
15/08/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $2 New Target: $1 Maintain
15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade

The stock decreased 5.87% or $0.0393 during the last trading session, reaching $0.6307. About 4.00M shares traded or 665.12% up from the average. aTyr Pharma, Inc. (NASDAQ:LIFE) has declined 76.28% since November 10, 2017 and is downtrending. It has underperformed by 91.90% the S&P500.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $18.83 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

More important recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: Globenewswire.com which released: “aTyr Pharma Announces Leadership Transition” on October 15, 2018, also Globenewswire.com published article titled: “aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting”, Seekingalpha.com published: “ATyr Pharma scientific chief bids adieu” on October 15, 2018. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) was released by: Nasdaq.com and their article: “aTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018” with publication date: November 08, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>